Literature DB >> 19299726

Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions.

Theo Rispens1, Pleuni Ooievaar-De Heer, Ellen Vermeulen, Janine Schuurman, Marijn van der Neut Kolfschoten, Rob C Aalberse.   

Abstract

The Fc fragment of IgG4 can interact with the Fc fragment of another IgG molecule. This interaction is a confounding factor when measuring IgG4 rheumatoid factor levels. Recently, we demonstrated that half-molecules of IgG4 can exchange to form a bispecific Ab. We expected these two phenomena to be related and investigated the physicochemical aspects of IgG4 Fc-Fc interactions. We found that IgG4 is >99% monomeric by size-exclusion chromatography; therefore, IgG4 Fc-Fc interactions in the fluid phase (if any) would be short-lived. However, (125)I-labeled IgG4 does bind to IgG1 and IgG4 coupled to a solid phase. By contrast, IgG1 does not bind to coupled IgG4. Furthermore, conditions that induce partial unfolding/dissociation of the CH3 domains enhance IgG4 Fc binding, suggesting that Fc binding is primarily CH3 mediated. IgG4 slowly associates with both IgG4 and IgG1 coupled to a biosensor chip. Remarkably, subsequent dissociation was much faster for IgG4 than for IgG1. Moreover, after binding of an IgG4 mAb to Sepharose-coupled Ag, we observed additional binding of IgG4 with irrelevant specificity, whereas similar binding was not observed with Ag-bound IgG1. We propose that the IgG4-IgG4 Fc interaction resembles an intermediate of the Fab-arm (half-molecule) exchange reaction that is stabilized because one of the IgG4 molecules is coupled to a solid phase. By contrast, IgG4 Fc recognizes IgG1 only after a conformational change that renders CH3(IgG1) accessible to an interaction with the CH3(IgG4). Such Fc interactions may enhance Ag binding of IgG4 in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299726     DOI: 10.4049/jimmunol.0804338

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.

Authors:  Boris Gorovits; Ying Wang; Liang Zhu; Marcela Araya; John Kamerud; Christopher Lepsy
Journal:  AAPS J       Date:  2019-06-03       Impact factor: 4.009

Review 2.  [Immunological principles of IgG4 related diseases].

Authors:  T Witte
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

Review 3.  [Immunological principles of IgG4 related diseases].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 4.  IgG4-associated vasculitis.

Authors:  Rodolfo Perez Alamino; Carlos Martínez; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 5.  Immunopathogenesis of membranous nephropathy: an update.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Semin Immunopathol       Date:  2014-04-09       Impact factor: 9.623

6.  Production of native bispecific antibodies in rabbits.

Authors:  Wei Wang; Ruihuan Xu; Jinming Li
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

Review 7.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

Review 8.  Pathophysiology of autoimmune pancreatitis.

Authors:  Raffaele Pezzilli; Nico Pagano
Journal:  World J Gastrointest Pathophysiol       Date:  2014-02-15

Review 9.  Molecular diagnosis: Implications for ophthalmology.

Authors:  James T Rosenbaum; Cailin H Sibley; Dongseok Choi; Christina A Harrington; Stephen R Planck
Journal:  Prog Retin Eye Res       Date:  2015-12-01       Impact factor: 21.198

Review 10.  The role of complement in membranous nephropathy.

Authors:  Hong Ma; Dana G Sandor; Laurence H Beck
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.